LTZ Therapeutics is an immunotherapy-focused global biotech company pursuing innovative therapies in oncology and autoimmune diseases. Pioneering a novel Myeloid Engager Platform that is guided by reverse translational science, emerging disease biology, and leveraging the power of myeloid cell subsets, particularly macrophages, which offer tremendous potential as an effective therapy to improve the lives of patients with the bold aim to one day eliminate cancer.